Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –
– Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million –
– Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –
– Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) –
– Conference Call and Webcast Today at 8:00 a.m. ET –
ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted continued commercial momentum for its bempedoic acid franchise, strong full-year revenue growth, and progress advancing its long-term strategic vision.
“2025 was a defining year for Esperion. We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin intolerant or statin-resistant patients and strengthened the durability of our business with important intellectual property and market access advances,” said Sheldon Koenig, Chief Executive Officer of Esperion. “Importantly, we used this momentum to chart our next chapter with Vision 2040 - a bold plan to build a multiproduct, innovation driven company with continued leadership in cardiometabolic disease and targeted expansion into rare hepatic and renal conditions. Our recently announced agreement to acquire Corstasis Therapeutics represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long-term Vision 2040.”
“Looking ahead, we’re investing against clear catalysts: deeper U.S. market penetration supported by robust payer coverage, advancement of our oral triple combination program designed to rival products on the market or in development and continued geographic expansion with our global partners. We are entering 2026 with confidence, discipline, and a long-term mindset focused on creating lasting value for patients, providers, and shareholders.”
Fourth Quarter 2025 Key Accomplishments and Recent Highlights
Advancing the U.S. Commercial Strategy
Most recently, the Company expanded its commercial opportunity with an agreement to acquire Corstasis Therapeutics, a biopharmaceutical company commercializing Enbumyst ™ (bumetanide nasal spray), the first and only nasal spray diuretic approved by the U.S. Food and Drug Administration (FDA) as a treatment for adults with edema associated with congestive heart failure (CHF), hepatic disease, and renal disease in adults. The proposed acquisition is aligned with Esperion’s Vision 2040 and is a compelling strategic fit with the Company’s established cardiometabolic commercial infrastructure and pipeline.
With an estimated 6.7 million American adults living with CHF and edema as one of the most common and defining clinical features of the disease, Enbumyst addresses a large and growing population that targets a U.S. market opportunity exceeding $4 billion. Learn more about the acquisition and Enbumyst here.
Esperion’s U.S. cardiovascular commercial business continued to demonstrate strong momentum in 2025, with meaningful gains in prescription growth, market access, and brand adoption across its bempedoic acid franchise.
Global Expansion
Esperion’s global expansion strategy accelerated in 2025, with strong performance from international partners and meaningful progress in regulatory approvals, reimbursement, and market launches across key regions.
R&D Pipeline
Esperion plans to advance its promising ACLY-focused pipeline, leveraging its established leadership in ACLY biology to pursue new therapeutic opportunities and develop next-generation inhibitors designed to address multiple life-threatening diseases. ACLY is a critical metabolic enzyme positioned at the intersection of nutrient catabolism and cholesterol and fatty acid biosynthesis, making it an attractive target for broad therapeutic intervention.
Publications and Presentations
Esperion continued to advance its scientific leadership in 2025, building on the robust clinical evidence supporting its bempedoic acid products through peer reviewed publications and data presentations designed to reach and educate the healthcare providers who treat patients with cardiometabolic disease.
Presentations
Publications
Fourth Quarter and Full Year 2025 Financial Results
Revenue
R&D Expenses
Selling, General and Administrative (SG&A) Expenses
Net Income (Loss)
Net Income (Loss) Per Share
Cash and Cash Equivalents
2026 Financial Outlook
The Company expects full year 2026 operating expenses to be in the range of $225 million to $255 million, including approximately $15 million in non-cash expenses related to stock compensation.
Conference Call and Webcast Information
Esperion will host a conference call and webcast today at 8:00 a.m. ET to discuss the financial results and business progress.
A live audio webcast can be accessed on the investor relations section of the Esperion website. The webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
INDICATION
NEXLIZET and NEXLETOL are indicated:
IMPORTANT SAFETY INFORMATION
Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, impact of acquisitions, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, business development, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Esperion Contact Information:
Investors & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438